Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Federal Trade Commission
Cantor Fitzgerald
Farmers Insurance
Citi
Chinese Patent Office
Chubb
Cerilliant
Mallinckrodt
US Department of Justice

Generated: October 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022271

« Back to Dashboard
NDA 022271 describes NESINA, which is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug and one Paragraph IV challenge. Additional details are available on the NESINA profile page.

The generic ingredient in NESINA is alogliptin benzoate. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the alogliptin benzoate profile page.

Summary for NDA: 022271

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:9
Formulation / Manufacturing:see details

Pharmacology for NDA: 022271

Suppliers and Packaging for NDA: 022271

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NESINA
alogliptin benzoate
TABLET;ORAL 022271 NDA AUTHORIZED GENERIC Perrigo New York Inc 45802-087 45802-087-65 30 TABLET, FILM COATED in 1 BOTTLE (45802-087-65)
NESINA
alogliptin benzoate
TABLET;ORAL 022271 NDA AUTHORIZED GENERIC Perrigo New York Inc 45802-103 45802-103-65 30 TABLET, FILM COATED in 1 BOTTLE (45802-103-65)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 6.25MG BASE
Approval Date:Jan 25, 2013TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 5, 2019
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE
Regulatory Exclusivity Expiration:Jan 25, 2018
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Patent:► SubscribePatent Expiration:Aug 9, 2016Product Flag?Substance Flag?Delist Request?
Patented Use:METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER

Expired Orange Book Patents for NDA: 022271



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Deloitte
US Army
Fish and Richardson
Cerilliant
Citi
Mallinckrodt
Cipla
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot